
## **ATP2A1** Antibody

PACO20017



Product Information	
Size:	Protein Background:
50ul	Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFC and VEGFD, and plays an essential role in adult lymphangiogenesis and in the development of the vascular network and the cardiovascular system during embryonic development. Promotes proliferation, survival and migration of endothelial cells, and regulates angiogenic sprouting. Signaling by activated FLT4 leads to enhanced production of VEGFC, and to a lesser degree VEGFA, thereby creating a positive feedback loop that enhances FLT4 signaling. Modulates KDR signaling by forming heterodimers. The secreted isoform 3 may function as a decoy receptor for VEGFC and/or VEGFD and play an important role as a negative regulator of VEGFC-mediated lymphangiogenesis and angiogenesis. Binding of vascular growth factors to isoform 1 or isoform 2 leads to the activation of several signaling cascades; isoform 2 seems to be less efficient in signal transduction, because it has a truncated C-terminus and therefore lacks several phosphorylation sites.
Reactivity:	
Human, Mouse	
Source:	
Rabbit	
lsotype:	
lgG	
Applications:	
ELISA, WB, IHC	Gene ID:
Recommended dilutions:	ATP2A1
ELISA:1:2000-1:5000, WB:1:200-1:1000, IHC:1:50-1:200	Uniprot
	O14983
	Synonyms:
	ATPase, Ca++ transporting, cardiac muscle, fast twitch 1
	Immunogen:
	Synthetic peptide of human ATP2A1.
	Storage:

-20° C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol



The image on the left is immunohistochemistry of paraffin-embedded Human brain tissue using PACO20017(ATP2A1 Antibody) at dilution 1/35, on the right is treated with synthetic peptide. (Original magnification: x—200).

Gel: 6%SDS-PAGE, Lysate: 40 ug, Lane 1-2: NIH/3T3 cells, LoVo cells, Primary antibody: PACO20017(ATP2A1 Antibody) at dilution 1/500, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 3 minutes.

The image on the left is immunohistochemistry of paraffin-embedded Human prostate cancer tissue using PACO20017(ATP2A1 Antibody) at dilution 1/35, on the right is treated with synthetic peptide. (Original magnification: x—200).